Alfonso Mendoza-Losana

The paper introduces OPTIKA, a high-throughput time-kill assay for assessing drug combinations against Mycobacterium tuberculosis, showing it outperforms traditional methods by over 1000-fold.

The paper analyzes whole-blood RNA-seq data from TB patients to identify rRNA transcriptomic signatures that change during anti-TB treatment, suggesting potential biomarkers for monitoring treatment response.

This paper identifies sanfetrinem cilexetil as a promising oral beta-lactam antibiotic for tuberculosis treatment through preclinical studies showing its activity against Mtb and potential for repurposing.

This study evaluates direct inhibitors of InhA (DIIs) for tuberculosis treatment, showing their efficacy comparable to isoniazid and their potential in new drug regimens.